aBerman Institute of Bioethics, Johns Hopkins University, Maryland;
bSchool of Medicine, Johns Hopkins University, Maryland;
cTI Verbatim Consulting, West Virginia;
dDepartment of International Health, Johns Hopkins University Bloomberg School of Public Health, Maryland; and
eUniversity of Maryland Carey School of Law, Maryland.
Correspondence to: Jeremy Sugarman, MD, MPH, MA, Johns Hopkins University, 1809 Ashland Avenue Baltimore, MD 21205 (e-mail: [email protected]).
Work on this project was supported by grant R01MH124590 (National Institutes of Mental Health).
J.S. is a member of Merck KGaA's Ethics Advisory Panel and Stem Cell Research Oversight Committee; a member of IQVIA's Ethics Advisory Panel; a member of Aspen Neurosciences Clinical Advisory Panel; a member of a Merck Data Monitoring Committee; and a consultant to Biogen. None of these activities are related to the material discussed in this article. The other authors have no disclosures.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.jaids.com).
